Physician profile
Nancy D Gordon
NPI 1679621734
$6,469.62
in general payments reported to CMS, 2019-2025
27 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $648 · 2021: $872 · 2022: $858 · 2023: $1,082 · 2024: $864 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,348.22 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $1,122.66 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $714.98 | 2019-2025 | Dupixent |
| Kaleo, INC. | $551.47 | 2019-2024 | Auvi-Q |
| Csl Behring | $523.82 | 2019-2024 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $388.32 | 2020-2025 | Hyqvia, Cuvitru, Aralast |
| Novartis Pharmaceuticals Corporation | $305.11 | 2019-2025 | |
| Genzyme Corporation | $218.14 | 2019-2025 | |
| Optinose US, INC. | $186.89 | 2019-2025 | |
| Amgen INC. | $151.22 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $114.94 | 2023-2024 | Ryaltris, Kloxxado |
| Biocryst US Sales Co., LLC | $107.57 | 2022-2023 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.11 | 2019-2022 | |
| Genentech USA, INC. | $91.28 | 2019-2022 | |
| Pfizer INC. | $83.52 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $82.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $78.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.07 | 2019-2021 | |
| Blueprint Medicines Corporation | $47.24 | 2022-2023 | Ayvakit |
| Bio Products Laboratory USA, INC. | $38.39 | 2019-2023 | Coagadex, Gammaplex |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.86 | 2021 | |
| Eyevance Pharmaceuticals LLC | $27.49 | 2021 | |
| Paratek Pharmaceuticals, INC. | $25.16 | 2025 | Xhance |
| Octapharma USA, INC. | $23.27 | 2019 | |
| Pharming Healthcare, INC. | $19.45 | 2019 | |
| Abbvie INC. | $14.29 | 2022 | |
| Alk-Abello, INC | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.